SEC Filing Summary: Hillstream BioPharma, Inc. (HILS)
Business Context and Reporting Period
This Form 8-K was filed by Hillstream BioPharma, Inc. on February 14, 2023. The registrant is a Delaware corporation listed on The Nasdaq Capital Market under the symbol "HILS" and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The primary event reported is the resolution of a listing deficiency. On October 27, 2022, the Company received notice from Nasdaq regarding non-compliance with the minimum bid price requirement (Listing Rule 5550(a)(2)). On February 14, 2023, the Company received confirmation from Nasdaq that it has regained compliance with this requirement, securing its continued listing on The Nasdaq Capital Market.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of future risks beyond the resolution of the specific listing issue. No unusual items or contingencies are disclosed in this document.
Investor Verification Checklist
- Verify the current trading price of HILS to ensure it remains above the Nasdaq minimum bid price threshold.
- Confirm the Company's continued compliance status on the Nasdaq website.
- Review the October 27, 2022, Form 8-K for the original details of the non-compliance notice.